Anesthesiology Research and Practice

Anesthesiology Research and Practice / 2011 / Article
Special Issue

Peripheral Nerve Blockade

View this Special Issue

Review Article | Open Access

Volume 2011 |Article ID 124898 | 12 pages | https://doi.org/10.1155/2011/124898

Perioperative Nerve Blockade: Clues from the Bench

Academic Editor: Gabriella Iohom
Received06 Jan 2011
Revised23 Mar 2011
Accepted06 May 2011
Published12 Jul 2011

Abstract

Peripheral and neuraxial nerve blockades are widely used in the perioperative period. Their values to diminish acute postoperative pain are established but other important outcomes such as chronic postoperative pain, or newly, cancer recurrence, or infections could also be influenced. The long-term effects of perioperative nerve blockade are still controversial. We will review current knowledge of the effects of blocking peripheral electrical activity in different animal models of pain. We will first go over the mechanisms of pain development and evaluate which types of fibers are activated after an injury. In the light of experimental results, we will propose some hypotheses explaining the mitigated results obtained in clinical studies on chronic postoperative pain. Finally, we will discuss three major disadvantages of the current blockade: the absence of blockade of myelinated fibers, the inappropriate duration of blockade, and the existence of activity-independent mechanisms.

1. Introduction

The major interest of regional anesthesia (central or peripheral nerve block) in clinical practice remains to replace or supplement general anesthesia for certain types of surgery and to provide efficient pain relief in the postoperative period. Being able to continue the block in the postoperative period allows a more effective pain control and a reduction of opioid-related side effects [1, 2]. While the improved patient comfort is undoubted, an overall improvement in long-term patient outcome is less evident and combining general anesthesia with a regional analgesic technique exposes the patient to the risk of both techniques. Since the concept of pain treatment as a fundamental human right has emerged, the use of invasive pain treatment is warranted already for the improvement of acute postoperative pain treatment [3]. Efficacy of nerve blockade on serious complications in the postoperative period (major morbidity or mortality) is hard to demonstrate because of their low incidence [4]. The possibility of preventing chronic postsurgical pain is becoming a major issue [3, 5, 6]. In the clinical research literature, there are only few reports showing a benefit of regional analgesic techniques on the incidence of chronic postoperative pain states. Two RCT demonstrated a reduction of the incidence of chronic postthoracotomy pain in patients treated with peri- and postoperative epidural analgesia as compared to patients without postoperative epidural analgesia [7, 8]. Further, a single paravertebral block reduced the incidence of postmastectomy pain one year following surgery as compared to a sham puncture [9]. Whereas the incidence of phantom limb pain after amputation was not influenced by epidural analgesia [10]. Surrogate outcomes are studied to increase the indications of regional analgesic techniques: length of hospital stay, improvement on long-term function after surgery (in orthopedics) and, newly, cancer recurrence [11], and reduction in surgical site infection [12]. Experimental research on humans and animals could help to define more clearly the working hypothesis of clinical trials and their design.

Current pain treatment should use a mechanistic-based approach. The best mechanistic knowledge in patient to-date is obtained from quantitative sensory testing (QST) where different modalities of sensation are tested. There is a gap between the sensory testing in human and the cellular and molecular vision offered in an experimental laboratory setting. The experimental setting also allows different types of blockade, using drugs with specificities on nerve fiber types, longer duration, or motor blockade, all of which cannot be tested on patients unless strong evidence has been gathered beforehand in experimental studies.

This paper is therefore intended to focus on the effect of nerve blockade on pain-related behavior and central changes that occur after peripheral tissue injury in animals (e.g., rats and mice) and build a bridge to clinical practice. We will try to point out some discoveries in bench research that would answer questions or lead to research ideas around the operating room.

2. Pathophysiology of Peripheral Discharges and Central Mechanisms of Persistent Pain

2.1. Peripheral Activity and Central Sensitization: A Potential Contribution to Chronic Postoperative Pain

The potential benefits of regional analgesic techniques rely on the ability of local anesthetics to reduce or abolish the peripheral input electrically transmitted by the nerve. Tissue injury and/or inflammation (with potential nerve lesion) during surgery lead to a massive input of action potentials along the primary afferents. The first relay of the information in the central nervous system (CNS) is the spinal cord dorsal horn. The glutamate release at the synapses in the dorsal horn induces a depolarization in the second-order neuron. If its amplitude is large enough, it triggers an action potential that conducts the information to higher centers. Cumulative afferent inputs gradually sensitize second-order neurons, which become more reactive to subsequent inputs. This global process of signal enhancement in the CNS is called central sensitization and encompasses increased membrane excitability, synaptic efficacy, and reduced inhibition. Central sensitization and its dependency on primary afferent activity has been extensively reviewed by Latremoliere and Woolf [13]. It is often described in 2 temporal phases an early short lasting, transcription-independent phase caused by phosphorylation mechanisms and a late longer lasting phase dependant on transcription and synthesis of new proteins [14]. Central sensitization is triggered by primary afferent release of glutamate which binds on postsynaptic ionotropic (AMPA (amino-3-hydroxy-5-methyl-4-isoxazole propionate), NMDA (N-methyl-D-Aspartate) and kainate), and metabotropic (mGluR 1–8, not all expressed in spinal cord) receptors. Under normal stimulation, the NMDA receptor is blocked by a magnesium (Mg++) ion in a voltage-dependent manner. Following sustained activity as in the case of surgery, the Mg++ block is released and glutamate can open the NMDA receptor leading to greater calcium entry in the spinal cord neuron, the first step of central sensitization. This is enhanced by the neuropeptides Substance P and CGRP, also released from primary afferents. The increase in cellular calcium in the dorsal horn neuron appears to be the trigger for the next step of central sensitization implicating activation of kinases (protein kinase A (PKA), C (PKC), or calmodulin kinase II (CaMKII)). These kinases phosphorylate different channels thereby increasing their trafficking to the membrane or changing their biophysical properties globally enhancing their response. Other targets in the later phases of the sensitization phenomenon include mitogen-activating kinases (MAPKs) such as extracellular signal-regulated kinase (ERK) and transcription factors finally leading to changes in gene expression.

2.2. Characterization of Spontaneous Discharges after Nerve Injury

Spontaneous activity occurs from the neuroma (unregulated regeneration of the nerve stump after injury) after nerve section [15, 16], and there have been numerous descriptions of increased peripheral activity after nerve injury, in different neuropathic pain models (Figure 1) and at different timepoints after injury. Most agree that ectopic activity in primary afferent after nerve injury arises from multiple sites (the neuroma, along the nerve, or in the dorsal root ganglion (DRG)) [17, 18]. However, there are still controversies about which type of fibers (injured versus noninjured fibers or myelinated versus unmyelinated fibers) [17]. Since the early recordings following axotomy, different animal models of neuropathic pain (Figure 1) were developed, many consisting of partial nerve lesions. They lead to various configurations between intact and injured nerve fibers. In chronic constriction injuries (CCI, originally described by Bennett and Xie [19] and modified by Mosconi and Kruger [20]), mostly myelinated fibers are injured, leaving neighboring C-fibers relatively undamaged [21]. In the spinal nerve ligation model (SNL) model [22], intact roots are in contact distally with the degenerating fibers of the injured roots and in the spared nerve injury (SNI) model [23] intact fibers are in contact with the proximal part of the injured nerves.

Summarizing all studies on peripheral nerve activity recordings is difficult but we will take out the general ideas. Most researchers consider A-fibers as the principal contributors to peripheral ectopic firing following nerve injury [2428]. Nevertheless, activity in the unmyelinated C-fibers was recorded either very early, during the first 15 minutes after a nerve lesion [29], or later, after a few days [30]. C-fiber activity was also recorded after spinal nerve ligation in the neighbored intact spinal nerve [31] or after stimulation of a nerve stump with nociceptive mediators [32]. This underlines the importance of uninjured fibers as provider of afferent inputs or of aggravating factors that we could also use as potential therapeutic target [25, 33, 34].

Is pain-related behavior linked to this ectopic firing? Indeed in neuropathic models, onset of activity is strongly related to the generation of pain [17, 31, 35, 36]. Ectopic discharges were even correlated with pain-related behavior at the early phase of nerve injury but not later on [37].

In a translational perspective, a nerve blockade, peripheral or neuraxial, should therefore cover impulse from both myelinated and unmyelinated fibers in the postoperative period. The minimal timeframe until peripheral input is no longer associated with pain-related behavior after surgery still has to be defined. Interestingly, for the clinical setting, Brennan’s group recently paralleled guarding behavior in rodents to spontaneous pain in postoperative patient. They were able to show that skin plus deep tissue incision induces a guarding behavior and increased spontaneous afferent activity which was not present in skin incision alone [38]. This brings to attention that spontaneous activity can appear in an inflammatory model without obvious nerve injury as seen in our daily surgical activity.

3. Advantages and Limits of Animal Research

The necessity of animal models has always been criticized [39, 40]. A few well-known failures to translate research findings into clinical trials, NK-1 antagonists [41], glycine site antagonist [42], or sodium channel blockers [43] remind us of the potential gaps between animals and humans. On the other hand, examples of successful translational research exist such as conotoxin, which revealed a new mechanism in pain development and lead to a new treatment [44]. New compounds are coming to clinical trial, nerve growth factor (NGF) inhibitor [45, 46], or transient receptor potential vanilloid receptor 1 (TRPV1) antagonists [47, 48].

Three current limitations in humans are cited by Mogil [40], (i) single neuron recording which gives valuable information is not obtainable in human, (ii) functional magnetic resonance imaging reaches a ceiling and high activity in neurons cannot be differentiated, and (iii) some regions of interest such as the spinal cord dorsal horn or the DRG are too small to be seen clearly. Therefore, most human studies characterize pain states and do not look at anatomical, biochemical, or physiological mechanisms. We are however able to see an increase in imaging studies which, together with quantitative sensory testing, represent the best mechanistic approach feasible in living patients and with technical improvement some limitations seen above will be overcome.

An obvious advantage of animals is the standardization of the injury and of the genetic and environmental background and avoiding any social factors. Nerve injuries on patients are heterogeneous and, therefore, difficult to study. We will here highlight the advantages and the limits of animal research specifically looking at nerve blockade issues.

3.1. Advantages of Animal Research

(a) Sustained Block
The influence of duration and initiation of epidural nerve blockade to prevent chronic changes after amputation has been studied clinically already 20 years ago with controversial results [10, 49]. For local anesthetics, delivery through slow release polymer is complicated and therefore peripheral or central nerve blockade lasting more than a few hours in patients implies the placement of a catheter. The length of a clinical block will depend on practical issues such as surveillance, costs, risks of catheter infection [50] or ambulatory surgery. In experimental research, slow release devices in development can already be used to block nerves over a few days [35]. By combining a slow release system (microspheres loaded with bupivacaine and a small amount of dexamethasone) with an entrapment (embedding the spheres in fibrin glue inside a silicon tube), we could achieve a complete sciatic nerve block for a week with complete recovery thereafter [51].

(b) Selective Block
As mentioned above, discharges originate in different fiber types depending on the injury model and timing. In clinical setting pain (nociceptive), specific blockade is achieved by reducing the concentration of the local anesthetics. Lots of research is ongoing to discover blockers whose targets are specifically expressed on nociceptors such as TRPV1 or specific isoforms of sodium channels.
TRPV1 can be blocked by an agonist as capsaicin or resiniferatoxin (RTX) which induces a desensitization of the nerve fiber for a longer period. In our hands, RTX directly applied on the sciatic nerve induced a selective block to heat stimulation for 3 days without affecting the response to mechanical stimulation or impairing motor ability. From the 9 voltage-gated sodium channels currently described (Nav1.1–1.9), Nav1.7, 1.8, and 1.9 are almost selectively expressed on nociceptors. No specific blocker of these channels has yet completed clinical trials successfully but compounds are still being tested [52]. These methods of selectively blocking nociceptors are not used in the perioperative setting, yet but in research they are useful tools to study the influence of selective fibers on the mechanisms of pain.

(c) Evaluation during the Blockade
Motor/sensitive block and pain levels can be assessed during peripheral or central nerve blockade whereas long-term outcomes as chronic pain or functional recovery can be checked later. We know many plastic changes occur in the perioperative period. In animals, tissue can be harvested during the blockade to study which mechanism are changed.

(d) Electrophysiological Recordings
The most important effect of peripheral or central nerve blockade is impeding discharge to pass from periphery to the brain, thereby inhibiting pain. Fundamental research on pathophysiological mechanisms (ectopic electrical activity-dependant or -independent changes, location, and timing of nerve activity) can give hints to clinicians where to block, when, and for how long. Then, clinical trials based on these mechanisms could be designed. Besides observational studies on discharge characteristics in different models, electrophysiological recordings allow to study the effect of blockade on subsequent discharge patterns.

3.2. Limits in Animal Research

Behavioral studies in animals are not an easy task. Subject to interobserver and interindividual variability, they integrate many different aspects of the pain pathways (spinal withdrawal reflexes, spino-bulbospinal reflexes as jumping, simple innate behaviors as guarding or licking, or more complicated learned behaviors) depending on the test used. The limits often put forward in animal models are the following: assessment of evoked-pain behavior and not spontaneous pain, no vocalization in the audible range, or no characterization of symptoms. We have to be aware of the limitations when we transfer our results to a clinical application and stay humble when we want to claim the mechanisms in animals and humans are comparable. We hope for mechanistic research in human to improve and to guide our laboratory hypotheses.

4. Clues from the Bench

Detailed effects of blocks on nerve injury models are summarized in Table 1 and the description of the models in Figure 1. We will highlight the general ideas below.


AuthorYearDrugDurationRoutePreemptiveModelTime of effectEffect

Behavioral changes

I. Kissin1999N-b-tetracainesinglesaphenousyessaphenous transection7 dpiPrevention early pressure hyperalgesia, caused hyperalgesia alone at 10 d
LidocaineSinglesaphenousyessaphenous transection1 dpiPrevention early pressure hyperalgesia

Y. W. Yoon1996BupivacaineSingledorsal root L4/5 5 dpinoSNL L5/65 dpiL5: reduction of mechanical + cold allodynia and ongoing pain; L4: reduction of mechanical + cold allodynia

Z. Seltzer1991MarcaineSinglesciatic/
saphenous
yessciatic/
saphenous
transection
Autotomy is delayed and its magnitude decreased

P. M. Dougherty1991LidocaineSinglesciaticyesCCI3 and 10 dpiReduction in duration and magnitude of thermal hyperalgesia
LidocaineSinglesciaticyesSeltzer3 and 10 dpiNo effect

S. Abdi2000Lido/bupivacaineSinglelocal before or 4 dpiyes/no SNL L5/L61 d after tttReduction of mechanical allodynia, no long-term effect

J. M. Zhang2000LidocaineDuring 1 or 8 dDRG following injurynoDRG compression1–28 dpiReduction of mechanical allodynia and hyperalgesia ipsilaterally with partial effect contralaterally

L. Luo1995Lido/tocainideSingleityessciatic section42 d after tttNo effect on autotomy

S. R. Chaplan1995LidocaineSingleiv, it, local, 28 dpinoL5/L6 ligation21 d after tttReduction of mechanical allodynia only if plasma concentration was high enough, no long-term effect of local and it

J. Mao1992BupivacaineSinglesciatic, 3 dpinoCCI1 d after tttReduction of thermal hyperalgesia

J. M. Gonzalez-Darder1985MepivacaineSinglelocalyessciatic section7–70 dpiReduction and delay of autotomy

M. L. Sotgiu1995LidocaineSinglesciatic, iv or ivyesCCI21 dpiReduction in paw licking during 2-3 weeks, then no difference

I. Bileviciute-Ljungar1999LidocaineRepeatsciatic contra, 6 + 1 1  dpinoCCI36 dpiReduction of thermal hyperalgesia 3-4 d, small effect on pressure stimulation, reduction of autotomy 36 d

T. Yamamoto1993BupivacaineSinglesciaticyesCCItill 14 dpiDelaying of thermal hyperalgesia until day 14
BupivacaineSinglesciatic 15 min postnoCCI7 dpiNo effect on thermal hyperalgesia

M. R. Suter2003BupvacaineLong termsciatic/spheresyesSNI4 weeksNo effect on mechanical allodynia, thermal hyperalgesia, cold allodynia

Y. S. Lyu2000TTXSingleDRGnoChung L5 ligation2 h after tttReduction of mechanical allodynia, no long-term effect

S. R. Chaplan2003ZD7288Singleip, 7 dpinoSNL L5/61 day after tttReduction in mechanical allodynia for 2 h, no effect at 24 h

L. M. Batista2009LidocaineSinglesciaticyesCCI, nylonover 28 daysReduction of scratching, thermal hyperalgesia (noxious and non-noxious)

I. Sukhotinsky2004LidocaineSingleDRG L4 or L5noSNL280 minReduction allodynia from 2 to 280 min after ttt, more effective on L5 than on intact L4

S. Eschenfelder2000LidocaineSingledorsal root L5 before sectionyesSNL L557 dpiNo difference for mechanical hyperalgesia

Biochemical or electrophysiological changes

J. M. Zhang2004Lidocaine7 dip, pumpnoSNL7 and 14 dpiReduction in tyrosine hydroxylase staining
Lidocaine14 dsciatic, pumpyessciatic transection14 dpiReduction in tyrosine hydroxylase staining

C. T. Lin2009LidocaineSinglemedian nerveyesmedian nerve transection28 dpiDose dependent reduction of injury discharge pre and post electrical stimulation and of NPY and c-fos in cuneate nucleus

I. Omana-Zapata1997TTXSingleintravenoousnosciatic transection4–10 daysDose dependent reduction of ectopic activity

I. Bileviciute-Ljungar2001LidocaineSinglecontralateral subcutaneousnoCCI14 dpiWDR L4/5 neuron ipsilateral: spontaneous hyperactivity reduced for 60 min

L. A. Colvin2001AmethocainSingledorsal roots L2–6noCCI10–14 dpiNo effect on neuropeptide Y release in spinal cord (measurement period of 2 h)

J. Scholz2005Bupivacaine7 dsciatic, spheresyesSNI7 dpiDelay in apoptosis of inhibitory interneurons in the dorsal horn of spinal cord

Y. R. Wen2007Bupvacaine3 dsciatic, spheresyesSNI3 dpiInhibition of p38MAPK activation in microglia in the spinal cord dorsal horn

W. Xie2009Bupivacaine/TTXLong termsciatic/DRG pump 7dnoSNI/SNL1–10 dpiTTX: inhibition of NGF increase (DRG, d3) OX-42 (SC, d3) and GFAP (SC, d10); both: inhibition of glial activation (DRG, d1–10)

S. I. Chi1993Local anestheticsciatic or systemicnosciatic transection2 and 14 dpiReduction in c-fos immunoreactivity in dorsal horn of spinal cord

S. I. Chi1993Lidocainesciatic or systemicyessciatic transection2 dpiReduction in c-fos immunoreactivity in dorsal horn of spinal cord

M. R. Suter2009Bupivacaine/RTX2 dsciatic, spheresyesSNI2 dpiBupi: inhibition of microglia proliferation and p38MAPK activation in dorsal horn of spinal cord; RTX: no effect

Mixed outcomes

L. Liang2010TTXRepeatsciatic, dailyyeselectrical stimulationup to 35 dpiReduction of mechanical allodynia, GFAP-staining on DRG

B. A. Rooney2007LidocaineSingledorsal rootyesbilateral dorsal root L4/5 sectionup to 13 daysNo increase in excitatory amino acid 10 min post injury, reduction in mechanical allodynia

W. Xie2005BupivacaineLong termsciatic, after lesionnoCCI and SNIup to 70 d (CCI), 150 d (SNI)Reduction in mechanical and heat pain for 60 d (CCI + SNI), suppression of hyperactivity at 20–28 dpi in A and C fibers

W. Xie2005TTXLong termsciatic, TTX (pump 3 or 7 d) just after lesion or 10 d laternoCCI and SNIup to 70 d (CCI), 150 d (SNI)Reduction in mechanical and heat pain for 60 d (CCI + SNI), TTX 10 d effective only during infusion, suppression of hyperactivity at 20–28 dpi in A and C fibers

R. W. Colburn1997BupivacaineRepeatspinal nerve before cut + before closureyesspinal nerve cryoneurolysis10 dpiReduction of microglial, but only minimal on astrocytic response, no effect on mechanical allodynia

S. Lee2007LidocaineSinglespinal nerve, ityesSNL L5/61–4 dpiDelay in mechanical allodynia by 1–4 d

C. Sato2008RopivacaineRepeatepidural, daily 7–17 dpinoCCIsince 11 dpiRelief of thermal hyperalgesia, small reduction of mechanical allodynia, NGF increase in DRG with ropivacaine

W. Xie2007TTX7 dsciatic, pumpyessciatic transection35–49 dpiReduction of hyperexcitability of large and medium cells and sympathetic sprouting. No change in C fiber through TTX

4.1. Effects of Timing and Duration of Block on Behavior

(i) Effect of Timing
The question of whether a nerve blockade has to be effective before or only after surgery is still unresolved. Few experimental studies compared the exact same treatment given before and after lesion. Fletcher et al. demonstrated a better effect on hyperalgesia when injecting bupivacaine in the paw before than after carrageenan [53]. The difference was even sustained when a second dose of carrageenan was injected a week later [54]. This underlines that priming of the nociceptive or sensitive system can be induced by a first injury without being noticed until it is unraveled by the magnified response to a second insult. In a model of intravesical acrolein injection, the timing of lidocaine injection influenced the referred mechanical hyperalgesia on the hindpaws but not the biochemical changes in the bladder itself [55], which points to activity dependant phenomenon or not. Pain mechanisms also change during development: a nerve blockade was done before or after a paw incision in 2-week or 4-week-old rat pups, the preinjury block was only more effective in the 2 weeks old pups [56]. Short block before injury reduced long-term pain-related behavior in the CCI model [5759], but not in the partial sciatic nerve ligation (PSNL) [57], SNL [60], or spinal nerve cryoneurolysis models [61]. Sometimes the block only delayed heat hyperalgesia in the CCI [62] or mechanical allodynia in the SNL [63]. In the pain clinic, as opposed to the perioperative setting, preventive block cannot be done and we want to know if nerve blockade is useful once pain is established. This is a fundamental pathophysiological issue to know if peripheral inputs still contribute to maintenance of pain or if pain has become a self-maintained central process. Local anesthetic on the dorsal root or spinal nerve after establishment of neuropathic pain could alleviate transiently mechanical and cold allodynia after SNL [34, 60] and inhibiting distal afferent in the CCI model was effective on heat hyperalgesia [64].
The clinical implication of these results is that it is probably useful to perform a nerve blockade before the surgery rather than only starting after. Even if the pain is already established it is worth to use peripheral nerve blockade to test if peripheral nerve activity still participates to the pain process.

(ii) Effect of Duration
Apart from the question of when to commence the block, the duration of any perioperative nerve blockade is often questioned. To answer, studies compare the same treatment for short versus long period. In animal inflammatory pain models, repeated injections or bupivacaine-microspheres but not a single injection of bupivacaine reduced pain behavior [6567]. In the paw incision model, which simulates inflammatory postoperative pain, longer block is more effective for relieving primary and secondary hyperalgesia [68]. For neuropathic pain, a one-week-long peripheral nerve blockade in the SNI model did not prevent pain-related behavior [51], whereas slow release bupivacaine placed at the time of lesion could prevent it in the same model and in the CCI [35].

Clinically, the suspicion that a longer block of nociceptive input could possibly prevent the development of chronic pain states has newly been discussed in the context of phantom limb pain after amputation. While older studies never managed to demonstrate a beneficial effect of epidural or peripheral nerve blocks, a recent observational study revealed astonishingly few patients suffering from phantom limb pain one year after lower limb amputation with prolonged peripheral nerve block performed as peri- and postoperative pain treatment (median duration of block 30 days) [69]. There are clinical and experimental arguments in favor of a long-term block but the duration with the best ratio of risk/benefit has yet to be found.

4.2. Biochemical Changes Affected by Blockade

During the period of a regional blockade, behavioral analysis is difficult due to the sensory impairment. Animal research allows observation of changes occurring along the pain pathways during that period by means of tissue collection and analysis. Early signs of neuronal activation in the spinal cord assessed by increased labeling of c-fos (a transcription factor that leads to expression of proteins) is reduced by nerve blockade in inflammatory [70] and postoperative [71] models of pain. Cyclo-oxygenase 2 (COX2) induction and production of prostaglandin E2 (PGE2) in the CNS is also dependent on peripheral nerve inputs [72, 73]. In the SNI model, we found a sciatic nerve blockade which reduces the apoptotic cell death in the spinal cord dorsal horn. This cell death affects inhibitory interneurons. It participates in the disinhibition process involved in the hyperexcitability of the system leading to pain-related behavior. Sadly, the cell death reduction is not long-lasting but only postponed until the end of the block [74]. Microglia and astrocytes, 2 types of glial cells (nonneuronal cell population of the CNS) have been implicated in pain processing [75, 76]. They are generally said to be activated in the context of pain. This activation was reduced in neuropathic pain model through peripheral nerve blockade [77, 78].

The idea of a magic bullet curing all pain has vanished. Therefore, categorizing specific aspects of sensitization processes into activity-dependent or -independent phenomena is useful to know when to use a blockade. These results also favor the concept of multimodal analgesia combining peripheral or central nerve blockade to systemic drugs on various targets.

4.3. Effects of Specific Block

In clinical postoperative setting, we adjust the concentration of local anesthetic to obtain a selective nociceptive blockade, which does not block nerve activity arising in thicker myelinated fibers. The paralysis of the limb induced by A-β fibers blockade cannot be accepted for a long period due to risk of sore lesions, loss of muscle mass hindering rehabilitation, and masking of complications. Indeed, complications of nerve blockade (nerve injury, hematoma, infection) are suspected when a motor deficit appears or persists [79].

In the SNI model, we compared the effect of complete block (using bupivacaine) to specific nociceptive block with RTX (TRPV1 agonist, inducing desensitization of the receptor). Microglial activation was reduced only by the complete block [80]. Tetrodotoxin (TTX) is a sodium channel blocker. Nociceptive fibers contain TTX-resistant sodium channels, and, therefore, myelinated fibers are preferentially blocked by TTX. TTX could prevent neuropathic pain-related behavior after CCI, SNL, and stimulation-induced pain [35, 81], but failed to reduced flinching in an inflammatory model compared to lidocaine [82]. These examples from animal blockade of specific nerve type highlight the paramount importance of thick myelinated fibers in sensitization processes especially in neuropathic pain. Indeed, we mentioned ectopic activity in myelinated axons after injury coincides with tactile allodynia [37].

We believe partial blockade such as currently performed, especially with an epidural, could be a reason of failure to prevent chronic postoperative pain despite using pre-emptive long-term block. Older clinical studies already pointed the differential effect of epidural versus spinal intensity of blockade. When both techniques are used at levels were cold and pinprick sensation is abolished, temporal summation is conserved in the epidural group, showing sensitization process might occur in the background of a painless patient [83, 84].

4.4. Other Effects of Nerve Block

Local anesthetics have many systemic or local properties besides impeding nerve conduction through voltage-gated sodium channels inhibition.

(i) The Anti-Inflammatory Effects of Nerve Blockade
The systemic inflammation tested by the levels of cytokines in the blood is reduced by bupivacaine, and this effect is systemic as ipsi, contralateral block and even contralateral intramuscular injection is effective [85]. In a human model of secondary hyperalgesia, local anesthetic had a systemic effect [86] which is clinically relevant as area of hyperalgesia in the acute postoperative period correlates with the incidence of postoperative chronic pain [8789].

(ii) Axonal Transport
Besides electric discharges axonal transport is another way of signaling a peripheral nerve injury to the CNS. Experimental axonal transport block could influence behavioral and glial changes after nerve injury [90]. Recently bupivacaine has been shown in vivo to inhibit the retrograde transport of TNFα after an inflammatory insult [91].

These less known pharmacologic properties of local anesthetics may contribute to the often observed “therapeutic effect” of local anesthetics injection in interventional pain management of certain chronic pain patients, such as facet joint nerve blocks (a) or epidural infiltrations (b), were local anesthetic administration alone often show the same favorable results as their coadministration with corticosteroids. It is also in this context, that previously performed randomized “placebo” controlled trials with negative results comparing the beneficial effect of the combined administration of corticosteroids and local anesthetics with patients receiving local anesthetics alone, as for example for cervical periradicular injections (c), lacked a real placebo group.

5. Conclusions and Back to Bedside

In clinical practice, nerve blocks are effective for treatment of acute postoperative pain but their impact on the prevention of chronic postoperative pain shows conflicting results. This paper intended to highlight some of the factors found in experimental studies. The main reason is the blockade limited to nociceptors with absence of blockade of myelinated thicker afferents. The latter account for most of the afferent activity after injury and experimental evidence show they participate in pain related behavior. Perioperative block limited to nociceptive fibers reduces the acute pain and we are maybe missing the sensitization phenomena that occur insidiously at the same time through the myelinated afferents, driving the chronification of the pain process. We mentioned the recent study with long-term block of all fibers [69], although only observational, giving encouraging results on chronic outcomes. For postoperative epidural analgesia, it will not be possible to fully block the inputs over a few days but for peripheral nerve blockade a more intense block can be considered. We have to define the best duration of both peripheral and epidural blockade balancing the advantages of inhibiting some central processes with the risks inherent to these techniques (infection, local anesthetic toxicity, etc.). With regards to the failure of some regional anesthesia techniques we have to keep in mind that some changes might be activity-independent and must, therefore, be addressed by other means. This involves multimodal analgesia combining complementary treatment associating systemic drugs to the regional technique.

Acknowledgment

This paper was supported by the Swiss National Science Foundation (Swiss Pain Consortium, SPUM grant, 33CM30-124117), Bern, Switzerland.

References

  1. B. M. Block, S. S. Liu, A. J. Rowlingson, A. R. Cowan, J. A. Cowan, and C. L. Wu, “Efficacy of postoperative epidural analgesia: a meta-analysis,” Journal of the American Medical Association, vol. 290, no. 18, pp. 2455–2463, 2003. View at: Publisher Site | Google Scholar
  2. J. M. Richman, S. S. Liu, G. Courpas et al., “Does continuous peripheral nerve block provide superior pain control to opioids? A meta-analysis,” Anesthesia and Analgesia, vol. 102, no. 1, pp. 248–257, 2006. View at: Publisher Site | Google Scholar
  3. M. J. Barrington and D. A. Scott, “Do we need to justify epidural analgesia beyond pain relief?” The Lancet, vol. 372, no. 9638, pp. 514–516, 2008. View at: Publisher Site | Google Scholar
  4. P. F. White and H. Kehlet, “Postoperative pain management and patient outcome: time to return to work!,” Anesthesia and Analgesia, vol. 104, no. 3, pp. 487–489, 2007. View at: Publisher Site | Google Scholar
  5. H. Kehlet, T. S. Jensen, and C. J. Woolf, “Persistent postsurgical pain: risk factors and prevention,” Lancet, vol. 367, no. 9522, pp. 1618–1625, 2006. View at: Publisher Site | Google Scholar
  6. A. Hadzic, T. T. Houle, X. Capdevila, and B. M. Ilfeld, “Femoral nerve block for analgesia in patients having knee arthroplasty,” Anesthesiology, vol. 113, no. 5, pp. 1014–1015, 2010. View at: Publisher Site | Google Scholar
  7. H. Obata, S. Saito, N. Fujita, Y. Fuse, K. Ishizaki, and F. Goto, “Epidural block with mepivacaine before surgery reduces long-term post- thoracotomy pain,” Canadian Journal of Anaesthesia, vol. 46, no. 12, pp. 1127–1132, 1999. View at: Google Scholar
  8. M. Şentürk, P. E. Özcan, G. K. Talu et al., “The effects of three different analgesia techniques on long-term postthoracotomy pain,” Anesthesia and Analgesia, vol. 94, no. 1, pp. 11–15, 2002. View at: Google Scholar
  9. P. M. Kairaluoma, M. S. Bachmann, P. H. Rosenberg, and P. J. Pere, “Preincisional paravertebral block reduces the prevalence of chronic pain after breast surgery,” Anesthesia and Analgesia, vol. 103, no. 3, pp. 703–708, 2006. View at: Publisher Site | Google Scholar
  10. L. Nikolajsen, S. Ilkjaer, J. H. Christensen, K. Krøner, and T. S. Jensen, “Randomised trial of epidural bupivacaine and morphine in prevention of stump and phantom pain in lower-limb amputation,” Lancet, vol. 350, no. 9088, pp. 1353–1357, 1997. View at: Publisher Site | Google Scholar
  11. A. Gottschalk, S. Sharma, J. Ford, M. E. Durieux, and M. Tiouririne, “The role of the perioperative period in recurrence after cancer surgery,” Anesthesia and Analgesia, vol. 110, no. 6, pp. 1636–1643, 2010. View at: Publisher Site | Google Scholar
  12. C.-C. Chang, H.-C. Lin, H.-W. Lin, and H.-C. Lin, “Anesthetic management and surgical site infections in total hip or knee replacement: a population-based study,” Anesthesiology, vol. 113, no. 2, pp. 279–284, 2010. View at: Publisher Site | Google Scholar
  13. A. Latremoliere and C. J. Woolf, “Central sensitization: a generator of pain hypersensitivity by central neural plasticity,” Journal of Pain, vol. 10, no. 9, pp. 895–926, 2009. View at: Publisher Site | Google Scholar
  14. C. J. Woolf and M. W. Salter, “Neuronal plasticity: increasing the gain in pain,” Science, vol. 288, no. 5472, pp. 1765–1768, 2000. View at: Publisher Site | Google Scholar
  15. P. D. Wall, S. Waxman, and A. I. Basbaum, “Ongoing activity in peripheral nerve: injury discharge,” Experimental Neurology, vol. 45, no. 3, pp. 576–589, 1974. View at: Google Scholar
  16. P. D. Wall and M. Devor, “Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats,” Pain, vol. 17, no. 4, pp. 321–339, 1983. View at: Publisher Site | Google Scholar
  17. M. Devor, “Responses of nerves to injury in relation to neuropathic pain,” in Textbook of Pain, S. B. McMahon and M. Koltzenburg, Eds., pp. 905–928, Elsevier, New York, NY, USA, 5th edition, 2006. View at: Google Scholar
  18. R. Amir, J. D. Kocsis, and M. Devor, “Multiple interacting sites of ectopic spike electrogenesis in primary sensory neurons,” Journal of Neuroscience, vol. 25, no. 10, pp. 2576–2585, 2005. View at: Publisher Site | Google Scholar
  19. G. J. Bennett and Y. K. Xie, “A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man,” Pain, vol. 33, no. 1, pp. 87–107, 1988. View at: Google Scholar
  20. T. Mosconi and L. Kruger, “Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations,” Pain, vol. 64, no. 1, pp. 37–57, 1996. View at: Publisher Site | Google Scholar
  21. K. C. Kajander and G. J. Bennett, “Onset of a painful peripheral neuropathy in rat: a partial and differential deafferentation and spontaneous discharge in Aβ and Aδ primary afferent neurons,” Journal of Neurophysiology, vol. 68, no. 3, pp. 734–744, 1992. View at: Google Scholar
  22. K. Chung, H. J. Kim, H. S. Na, M. J. Park, and J. M. Chung, “Abnormalities of sympathetic innervation in the area of an injured peripheral nerve in a rat model of neuropathic pain,” Neuroscience Letters, vol. 162, no. 1-2, pp. 85–88, 1993. View at: Publisher Site | Google Scholar
  23. I. Decosterd and C. J. Woolf, “Spared nerve injury: an animal model of persistent peripheral neuropathic pain,” Pain, vol. 87, no. 2, pp. 149–158, 2000. View at: Publisher Site | Google Scholar
  24. K. L. Seburn, P. A. Catlin, J. F. Dixon, M. H. Lee, M. S. Matteson, and T. C. Cope, “Decline in spontaneous activity of group Aαβ sensory afferents after sciatic nerve axotomy in rat,” Neuroscience Letters, vol. 274, no. 1, pp. 41–44, 1999. View at: Publisher Site | Google Scholar
  25. M. Michaelis, X. Liu, and W. Jänig, “Axotomized and intact muscle afferents but no skin afferents develop ongoing discharges of dorsal root ganglion origin after peripheral nerve lesion,” Journal of Neuroscience, vol. 20, no. 7, pp. 2742–2748, 2000. View at: Google Scholar
  26. M. Tal and E. Eliav, “Abnormal discharge originates at the site of nerve injury in experimental constriction neuropathy (CCI) in the rat,” Pain, vol. 64, no. 3, pp. 511–518, 1996. View at: Publisher Site | Google Scholar
  27. X. Liu, K. Chung, and J. M. Chung, “Ectopic discharges and adrenergic sensitivity of sensory neurons after spinal nerve injury,” Brain Research, vol. 849, no. 1-2, pp. 244–247, 1999. View at: Publisher Site | Google Scholar
  28. H. Chul Han, D. Hyun Lee, and J. Mo Chung, “Characteristics of ectopic discharges in a rat neuropathic pain model,” Pain, vol. 84, no. 2-3, pp. 253–261, 2000. View at: Publisher Site | Google Scholar
  29. K. H. Blenk, W. Jänig, M. Michaelis, and C. Vogel, “Prolonged injury discharge in unmyelinated nerve fibres following transection of the sural nerve in rats,” Neuroscience Letters, vol. 215, no. 3, pp. 185–188, 1996. View at: Publisher Site | Google Scholar
  30. M. Zimmermann, “Pathobiology of neuropathic pain,” European Journal of Pharmacology, vol. 429, no. 1–3, pp. 23–37, 2001. View at: Publisher Site | Google Scholar
  31. G. Wu, M. Ringkamp, T. V. Hartke et al., “Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers,” The Journal of Neuroscience, vol. 21, no. 8, p. RC140, 2001. View at: Google Scholar
  32. M. Michaelis, C. Vogel, K. H. Blenk, and W. Jänig, “Algesics excite axotomised afferent nerve fibres within the first hours following nerve transection in rats,” Pain, vol. 72, no. 3, pp. 347–354, 1997. View at: Publisher Site | Google Scholar
  33. Z. Ali, M. Ringkamp, T. V. Hartke et al., “Uninjured C-fiber nociceptors develop spontaneous activity and α-adrenergic sensitivity following L spinal nerve ligation in monkey,” Journal of Neurophysiology, vol. 81, no. 2, pp. 455–466, 1999. View at: Google Scholar
  34. Y. W. Yoon, H. S. Na, and J. M. Chung, “Contributions of injured and intact afferents to neuropathic pain in an experimental rat model,” Pain, vol. 64, no. 1, pp. 27–36, 1996. View at: Publisher Site | Google Scholar
  35. W. Xie, J. A. Strong, J. T. A. Meij, J. M. Zhang, and L. Yu, “Neuropathic pain: early spontaneous afferent activity is the trigger,” Pain, vol. 116, no. 3, pp. 243–256, 2005. View at: Publisher Site | Google Scholar
  36. C. Ma, Y. Shu, Z. Zheng et al., “Similar electrophysiological changes in axotomized and neighboring intact dorsal root ganglion neurons,” Journal of Neurophysiology, vol. 89, no. 3, pp. 1588–1602, 2003. View at: Publisher Site | Google Scholar
  37. Q. Sun, H. Tu, G. G. Xing, J. S. Han, and Y. Wan, “Ectopic discharges from injured nerve fibers are highly correlated with tactile allodynia only in early, but not late, stage in rats with spinal nerve ligation,” Experimental Neurology, vol. 191, no. 1, pp. 128–136, 2005. View at: Publisher Site | Google Scholar
  38. J. Xu and T. J. Brennan, “Comparison of skin incision vs. skin plus deep tissue incision on ongoing pain and spontaneous activity in dorsal horn neurons,” Pain, vol. 144, no. 3, pp. 329–339, 2009. View at: Publisher Site | Google Scholar
  39. J. S. Mogil, “Animal models of pain: progress and challenges,” Nature Reviews Neuroscience, vol. 10, no. 4, pp. 283–294, 2009. View at: Publisher Site | Google Scholar
  40. J. S. Mogil, K. D. Davis, and S. W. Derbyshire, “The necessity of animal models in pain research,” Pain, vol. 151, no. 1, pp. 12–17, 2010. View at: Publisher Site | Google Scholar
  41. R. Hill, “NK1 (substance P) receptor antagonists—why are they not analgesic in humans?” Trends in Pharmacological Sciences, vol. 21, no. 7, pp. 244–246, 2000. View at: Publisher Site | Google Scholar
  42. M. S. Wallace, M. C. Rowbotham, N. P. Katz et al., “A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain,” Neurology, vol. 59, no. 11, pp. 1694–1700, 2002. View at: Google Scholar
  43. M. S. Wallace, M. Rowbotham, G. J. Bennett, T. S. Jensen, R. Pladna, and S. Quessy, “A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain,” Journal of Pain, vol. 3, no. 3, pp. 227–233, 2002. View at: Publisher Site | Google Scholar
  44. R. L. Rauck, M. S. Wallace, A. W. Burton, L. Kapural, and J. M. North, “Intrathecal ziconotide for neuropathic pain: a review,” Pain Practice, vol. 9, no. 5, pp. 327–337, 2009. View at: Publisher Site | Google Scholar
  45. N. E. Lane, T. J. Schnitzer, C. A. Birbara et al., “Tanezumab for the treatment of pain from osteoarthritis of the knee,” New England Journal of Medicine, vol. 363, no. 16, pp. 1521–1531, 2010. View at: Publisher Site | Google Scholar
  46. J. N. Wood, “Nerve growth factor and pain,” New England Journal of Medicine, vol. 363, no. 16, pp. 1572–1573, 2010. View at: Publisher Site | Google Scholar
  47. N. R. Gavva, R. Tamir, Y. Qu et al., “AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties,” Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 1, pp. 474–484, 2005. View at: Publisher Site | Google Scholar
  48. G. Y. Wong and N. R. Gavva, “Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks,” Brain Research Reviews, vol. 60, no. 1, pp. 267–277, 2009. View at: Publisher Site | Google Scholar
  49. S. Bach, M. F. Noreng, and N. U. Tjellden, “Phantom limb pain in amputees during the first 12 months following limb amputation, after preoperative lumbar epidural blockade,” Pain, vol. 33, no. 3, pp. 297–301, 1988. View at: Google Scholar
  50. X. Capdevila, P. Pirat, S. Bringuier et al., “Continuous peripheral nerve blocks in hospital wards after orthopedic surgery: a multicenter prospective analysis of the quality of postoperative analgesia and complications in 1,416 patients,” Anesthesiology, vol. 103, no. 5, pp. 1035–1045, 2005. View at: Publisher Site | Google Scholar
  51. M. R. Suter, M. Papaloïzos, C. B. Berde et al., “Development of neuropathic pain in the rat spared nerve injury model is not prevented by a peripheral nerve block,” Anesthesiology, vol. 99, no. 6, pp. 1402–1408, 2003. View at: Publisher Site | Google Scholar
  52. W. A. Schmalhofer, J. Calhoun, R. Burrows et al., “ProTx-II, a selective inhibitor of Na1.7 sodium channels, blocks action potential propagation in nociceptors,” Molecular Pharmacology, vol. 74, no. 5, pp. 1476–1484, 2008. View at: Publisher Site | Google Scholar
  53. D. Fletcher, V. Kayser, and G. Guilbaud, “Influence of timing of administration on the analgesic effect of bupivacaine infiltration in carrageenin-injected rats,” Anesthesiology, vol. 84, no. 5, pp. 1129–1137, 1996. View at: Publisher Site | Google Scholar
  54. D. Fletcher, V. Kayser, and G. Guilbaud, “The influence of the timing of bupivacaine infiltration on the time course of inflammation induced by two carrageenin injections seven days apart,” Pain, vol. 69, no. 3, pp. 303–309, 1997. View at: Publisher Site | Google Scholar
  55. S. D. Guerios, Z. Y. Wang, K. Boldon, W. Bushman, and D. E. Bjorling, “Lidocaine prevents referred hyperalgesia associated with cystitis,” Neurourology and Urodynamics, vol. 28, no. 5, pp. 455–460, 2009. View at: Publisher Site | Google Scholar
  56. D. G. Ririe, D. Barclay, H. Prout, C. Tong, J. R. Tobin, and J. C. Eisenach, “Preoperative sciatic nerve block decreases mechanical allodynia more in young rats: is preemptive analgesia developmentally modulated?” Anesthesia and Analgesia, vol. 99, no. 1, pp. 140–145, 2004. View at: Google Scholar
  57. P. M. Dougherty, C. J. Garrison, and S. M. Carlton, “Differential influence of local anesthetic upon two models of experimentally induced peripheral mononeuropathy in the rat,” Brain Research, vol. 570, no. 1-2, pp. 109–115, 1992. View at: Google Scholar
  58. L. D. M. Batista, I. M. Batista, J. P. Almeida, C. H. Carvalho, S. B. De Castro-Costa, and C. M. De Castro-Costa, “Preemptive analgesic effect of lidocaine in a chronic neuropathic pain model,” Arquivos de Neuro-Psiquiatria, vol. 67, no. 4, pp. 1088–1092, 2009. View at: Publisher Site | Google Scholar
  59. M. L. Sotgiu, A. Castagna, M. Lacerenza, and P. Marchettini, “Pre-injury lidocaine treatment prevents thermal hyperalgesia and cutaneous thermal abnormalities in a rat model of peripheral neuropathy,” Pain, vol. 61, no. 1, pp. 3–10, 1995. View at: Publisher Site | Google Scholar
  60. S. Abdi, D. H. Lee, S. K. Park, and J. M. Chung, “Lack of pre-emptive analgesic effects of local anaesthetics on neuropathic pain,” British Journal of Anaesthesia, vol. 85, no. 4, pp. 620–623, 2000. View at: Google Scholar
  61. R. W. Colburn, J. A. Deleo, A. J. Rickman, M. P. Yeager, P. Kwon, and W. F. Hickey, “Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat,” Journal of Neuroimmunology, vol. 79, no. 2, pp. 163–175, 1997. View at: Publisher Site | Google Scholar
  62. T. Yamamoto, N. Shimoyama, and T. Mizuguchi, “Role of the injury discharge in the development of thermal hyperesthesia after sciatic nerve constriction injury in the rat,” Anesthesiology, vol. 79, no. 5, pp. 993–1002, 1993. View at: Google Scholar
  63. S. E. Lee and J. H. Kim, “Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat,” Neuroscience Research, vol. 58, no. 3, pp. 245–249, 2007. View at: Publisher Site | Google Scholar
  64. J. Mao, D. D. Price, D. J. Mayer, J. Lu, and R. L. Hayes, “Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy,” Brain Research, vol. 576, no. 2, pp. 254–262, 1992. View at: Publisher Site | Google Scholar
  65. M. E. Gentili, J. X. Mazoit, K. Samii, and D. Fletcher, “The effect of a sciatic nerve block on the development of inflammation in carrageenan injected rats,” Anesthesia and Analgesia, vol. 89, no. 4, pp. 979–984, 1999. View at: Publisher Site | Google Scholar
  66. J. P. Estebe, M. E. Gentili, P. Le Corre, C. Leduc, J. P. Moulinoux, and C. Ecoffey, “Contralateral effect of amitriptyline and bupivacaine for sciatic nerve block in an animal model of inflammation,” British Journal of Anaesthesia, vol. 93, no. 5, pp. 705–709, 2004. View at: Publisher Site | Google Scholar
  67. J. P. Estèbe, M. E. Gentili, P. Le Corre, R. Le Verge, J. P. Moulinoux, and C. Ecoffey, “Sciatic nerve block with bupivacaine-loaded microspheres prevents hyperalgesia in an inflammatory animal model,” Canadian Journal of Anesthesia, vol. 49, no. 7, pp. 690–693, 2002. View at: Google Scholar
  68. C.-F. Wang, C. Pancaro, P. Gerner, and G. Strichartz, “Prolonged suppression of postincisional pain by a slow-release formulation of lidocaine,” Anesthesiology, vol. 114, no. 1, pp. 135–149, 2011. View at: Publisher Site | Google Scholar
  69. B. Borghi, M. D'Addabbo, P. F. White et al., “The use of prolonged peripheral neural blockade after lower extremity amputation: the effect on symptoms associated with phantom limb syndrome,” Anesthesia and Analgesia, vol. 111, no. 5, pp. 1308–1315, 2010. View at: Publisher Site | Google Scholar
  70. Y. P. Feng, K. Yang, and Y. Q. Li, “Activation of capsaicin receptors on the sciatic nerve induces FOS expression in the spinal dorsal horn of adult rats,” NeuroSignals, vol. 11, no. 3, pp. 151–157, 2002. View at: Publisher Site | Google Scholar
  71. K. Lykkegaard, B. Lauritzen, L. Tessem, P. Weikop, and O. Svendsen, “Local anaesthetics attenuates spinal nociception and HPA-axis activation during experimental laparotomy in pigs,” Research in Veterinary Science, vol. 79, no. 3, pp. 245–251, 2005. View at: Publisher Site | Google Scholar
  72. H. Beloeil, M. Gentili, D. Benhamou, and J. X. Mazoit, “The effect of a peripheral block on inflammation-induced prostaglandin E2 and cyclooxygenase expression in rats,” Anesthesia and Analgesia, vol. 109, no. 3, pp. 943–950, 2009. View at: Google Scholar
  73. E. Combettes, D. Benhamou, J. X. Mazoit, and H. Beloeil, “Comparison of a bupivacaine peripheral nerve block and systemic ketoprofen on peripheral inflammation and hyperalgesia in rats,” European Journal of Anaesthesiology, vol. 27, no. 7, pp. 642–647, 2010. View at: Publisher Site | Google Scholar
  74. J. Scholz, D. C. Broom, D.-H. Youn et al., “Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury,” Journal of Neuroscience, vol. 25, no. 32, pp. 7317–7323, 2005. View at: Publisher Site | Google Scholar
  75. R.-D. Gosselin, M. R. Suter, R.-R. Ji, and I. Decosterd, “Glial cells and chronic pain,” Neuroscientist, vol. 16, no. 5, pp. 519–531, 2010. View at: Publisher Site | Google Scholar
  76. M. R. Suter, Y. R. Wen, I. Decosterd, and R. R. Ji, “Do glial cells control pain?” Neuron Glia Biology, vol. 3, no. 3, pp. 255–268, 2007. View at: Publisher Site | Google Scholar
  77. Y. R. Wen, M. R. Suter, Y. Kawasaki et al., “Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model,” Anesthesiology, vol. 107, no. 2, pp. 312–321, 2007. View at: Publisher Site | Google Scholar
  78. W. Xie, J. A. Strong, and J. M. Zhang, “Early blockade of injured primary sensory afferents reduces glial cell activation in two rat neuropathic pain models,” Neuroscience, vol. 160, no. 4, pp. 847–857, 2009. View at: Publisher Site | Google Scholar
  79. J. M. Neal, C. M. Bernards, A. Hadzic et al., “ASRA practice advisory on neurologic complications in regional anesthesia and pain medicine,” Regional Anesthesia and Pain Medicine, vol. 33, no. 5, pp. 404–415, 2008. View at: Publisher Site | Google Scholar
  80. M. R. Suter, T. Berta, Y. J. Gao, I. Decosterd, and R. R. Ji, “Large A-fiber activity is required for microglial proliferation and p38 MAPK activation in the spinal cord: different effects of resiniferatoxin and bupivacaine on spinal microglial changes after spared nerve injury,” Molecular Pain, vol. 5, p. 53, 2009. View at: Google Scholar
  81. L. Liang, Z. Wang, N. Lü, J. Yang, Y. Zhang, and Z. Zhao, “Involvement of nerve injury and activation of peripheral glial cells in tetanic sciatic stimulation-induced persistent pain in rats,” Journal of Neuroscience Research, vol. 88, no. 13, pp. 2899–2910, 2010. View at: Publisher Site | Google Scholar
  82. C. S. Houck, A. Khodorova, A. M. Reale, G. R. Strichartz, and G. Davar, “Sensory fibers resistant to the actions of tetrodotoxin mediate nocifensive responses to local administration of endothelin-1 in rats,” Pain, vol. 110, no. 3, pp. 719–726, 2004. View at: Publisher Site | Google Scholar
  83. M. Curatolo, S. Petersen-Felix, L. Arendt-Nielsen, M. Fischer, and A. M. Zbinden, “Temporal summation during extradural anaesthesia,” British Journal of Anaesthesia, vol. 75, no. 5, pp. 634–635, 1995. View at: Google Scholar
  84. M. Curatolo, S. Petersen-Felix, L. Arendt-Nielsen, and A. M. Zbinden, “Spinal anaesthesia inhibits central temporal summation,” British Journal of Anaesthesia, vol. 78, no. 1, pp. 88–89, 1997. View at: Google Scholar
  85. H. Beloeil, R. R. Ji, and C. B. Berde, “Effects of bupivacaine and tetrodotoxin on carrageenan-induced hind paw inflammation in rats (part 2): cytokines and p38 mitogen-activated protein kinases in dorsal root ganglia and spinal cord,” Anesthesiology, vol. 105, no. 1, pp. 139–145, 2006. View at: Publisher Site | Google Scholar
  86. W. Koppert, S. Zeck, R. Sittl, R. Likar, R. Knoll, and M. Schmelz, “Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans,” Anesthesiology, vol. 89, no. 6, pp. 1345–1353, 1998. View at: Publisher Site | Google Scholar
  87. M. De Kock, P. Lavand'homme, and H. Waterloos, “'Balanced analgesia' in the perioperative period: is there a place for ketamine?” Pain, vol. 92, no. 3, pp. 373–380, 2001. View at: Publisher Site | Google Scholar
  88. M. De Kock, P. Lavand'homme, and H. Waterloos, “The short-lasting analgesia and long-term antihyperalgesic effect of intrathecal clonidine in patients undergoing colonic surgery,” Anesthesia and Analgesia, vol. 101, no. 2, pp. 566–572, 2005. View at: Publisher Site | Google Scholar
  89. P. Lavand'homme, M. De Kock, and H. Waterloos, “Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery,” Anesthesiology, vol. 103, no. 4, pp. 813–820, 2005. View at: Publisher Site | Google Scholar
  90. R. W. Colburn and J. A. DeLeo, “The effect of perineural colchicine on nerve injury-induced spinal glial activation and neuropathic pain behavior,” Brain Research Bulletin, vol. 49, no. 6, pp. 419–427, 1999. View at: Publisher Site | Google Scholar
  91. S. Deruddre, E. Combettes, J. P. Estebe et al., “Effects of a bupivacaine nerve block on the axonal transport of Tumor Necrosis Factor-alpha (TNF-α) in a rat model of carrageenan-induced inflammation,” Brain, Behavior, and Immunity, vol. 24, no. 4, pp. 652–659, 2010. View at: Publisher Site | Google Scholar

Copyright © 2011 M. R. Suter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

2517 Views | 904 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.